Capricor Therapeutics, Inc. CAPR

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
49/100
Developing

Ranked against 712 peers in Biotechnology

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also … Full CAPR analysis →

Key strengths

  • Operating Expense Control OpEx growth is controlled (score 0.65), demonstrating operating leverage.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.76), providing operational cushion.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 11.0th percentile with high volatility suggests weak pricing power or commoditized products.
  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.20), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
24
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where CAPR ranks in Biotechnology

Capricor Therapeutics, Inc. ranks #257 of 713 scored companies in Biotechnology by moat score — the top 36%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
253 Immuron Limited IMRN 49/100 Developing
254 Editas Medicine, Inc. EDIT 49/100 Developing
255 Generation Bio Co. GBIO 49/100 Developing
256 Barinthus Biotherapeutics plc BRNS 49/100 Developing
257 Capricor Therapeutics, Inc. CAPR 49/100 Developing
258 Nuvation Bio Inc. NUVB 49/100 Developing
259 Celcuity Inc. CELC 48/100 Developing
260 Context Therapeutics Inc. CNTX 48/100 Developing
261 Tyra Biosciences, Inc. TYRA 48/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How CAPR scores on the Corporate Default defenses

Pricing Power

Score 24 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 70 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 47 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 39 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 62 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 58 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding CAPR's moat

What is Capricor Therapeutics, Inc.'s moat score?

Capricor Therapeutics, Inc. (CAPR) scores 49 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #257 of 713 scored companies in Biotechnology, the top 36%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Cost Advantage (70/100) and its weakest is Pricing Power (24/100).

How does Capricor Therapeutics, Inc. compare with other Biotechnology companies?

Capricor Therapeutics, Inc. ranks #257 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Barinthus Biotherapeutics plc (BRNS) at 49 just above it and Nuvation Bio Inc. (NUVB) at 49 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Capricor Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Capricor Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and CAPR scores: Pricing Power (24), Cost Advantage (70), Customer Stickiness (47), Capital Efficiency (39), Resilience (62), Scale & Market Position (58). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000